Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Nu-Med Plus (NUMD) EBIT (2016 - 2021)

Nu-Med Plus' EBIT history spans 10 years, with the latest figure at -$112341.0 for Q4 2021.

  • Quarterly results put EBIT at -$112341.0 for Q4 2021, up 77.78% from a year ago — trailing twelve months through Dec 2021 was -$839445.0 (up 58.3% YoY), and the annual figure for FY2025 was -$48955.0, up 22.7%.
  • EBIT for Q4 2021 was -$112341.0 at Nu-Med Plus, up from -$118366.0 in the prior quarter.
  • In the past five years, EBIT ranged from a high of $3.9 million in Q4 2017 to a low of -$908467.0 in Q2 2020.
  • The 5-year median for EBIT is -$187208.5 (2018), against an average of -$74182.0.
  • The sharpest move saw EBIT surged 314.69% in 2017, then plummeted 279.0% in 2018.
  • Year by year, EBIT stood at $3.9 million in 2017, then plummeted by 109.12% to -$355401.0 in 2018, then soared by 42.12% to -$205704.0 in 2019, then plummeted by 145.73% to -$505482.0 in 2020, then skyrocketed by 77.78% to -$112341.0 in 2021.
  • According to Business Quant data, EBIT over the past three periods came in at -$112341.0, -$118366.0, and -$251990.0 for Q4 2021, Q3 2021, and Q2 2021 respectively.